News and Reports
-
SWIXX and Kyowa Kirin expand Partnership for Rare Disease Portfolio to 13 Countries in Europe
19 December 2022Download -
Mineralys Therapeutics Announces Positive Topline Phase 2 Data for MLS-101 in the Target-HTN Trial Evaluating the Treatment of Uncontrolled and Resistant Hypertension
16 November 2022Download -
Boditech Med and SphingoTec close global licensing agreement for kidney function biomarker Proenkephalin A 119-159 (penKid)
15 November 2022Download -
Swixx and Kyowa Kirin enter into Partnership for Rare Disease Medicines Portfolio in Poland
10 October 2022Download -
Shape Memory Medical Completes Enrollment in the AAA-SHAPE Early Feasibility Study
29 August 2022Download -
Upstream Bio Announces Dosing of First Patient in a Phase 1b Clinical Trial of UPB-101 in Asthma
9 August 2022Download -
Vascular Dynamics Completes $20 Million Equity Financing to Support Further Clinical Evaluations of MobiusHD Device
12 July 2022Download -
Galera Announces Results from Phase 1 Stage of GRECO-1 Trial of Rucosopasem with SBRT for NSCLC
29 June 2022Download -
Aculys Pharma initiates collaboration with Ubie with the aim of building a “sleep ecosystem”
29 June 2022Download -
Akoya Biosciences to Partner with Acrivon Therapeutics for the Clinical Development of Acrivon’s Proprietary OncoSignature® Test into a Companion Diagnostic
28 June 2022Download -
Acrivon Therapeutics Receives FDA Clearance for Innovative Phase 2 Trial to Treat Ovarian, Endometrial and Urothelial Cancer Patients Based on Predicted Sensitivity to ACR-368
22 June 2022Download -
Galecto Announces First Patient Enrolled in Phase 2 Trial of GB1211 in Combination with Atezolizumab for First-Line Treatment of NSCLC
16 June 2022Download -
Dren Bio Announces $65 Million Series B Financing to Advance its Lead Asset into the Clinic
14 June 2022Download -
Mineralys Therapeutics Closes $118 Million Oversubscribed Series B Financing to Advance the Development of Novel, Targeted Treatment for Hypertension
8 June 2022Download -
Bristol Myers Squibb to Acquire HBM Portfolio Company Turning Point Therapeutics for USD 4.1 billion in cash
3 June 2022Download -
Upstream Bio Launches with $200M Series A Financing to Advance Novel Therapeutics for Allergic and Inflammatory Diseases
2 June 2022Download -
Galera Announces Oral Presentation at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting Detailing Results from Phase 3 ROMAN Trial of Avasopasem
26 May 2022Download -
Pfizer to acquire HBM portfolio company Biohaven Pharmaceuticals in USD 11.6 billion deal
10 May 2022Download -
NiKang Therapeutics and Hansoh Pharma Announce Strategic Collaboration and License Agreement for NKT2152 in Greater China
3 May 2022Download -
Galera Announces Topline Results from Phase 2a AESOP Trial of Avasopasem for Chemoradiotherapy-Induced Esophagitis
2 May 2022Download -
Galecto Completes Enrollment in Global Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of IPF
26 April 2022Download -
SWIXX and JAZZ expand partnership
19 April 2022Download -
SWIXX and Blueprint Medicines enter into CEE + Greece agreement for AYVAKYT® (avapritinib)
11 April 2022Download -
iTeos Presents New Data for Anti-TIGIT Antibody, EOS-448/GSK4428859A, at the AACR Annual Meeting 2022
8 April 2022Download -
Galecto Completes Enrollment in Phase 1b/2a GULLIVER-2 Trial of its Selective, Oral Galectin-3 Inhibitor GB1211 in Liver Cirrhosis
29 March 2022Download